pancreatic-cancer

Ferrocene-Pyrazole hybrid compound induces ferroptosis and metabolic disruption in pancreatic cancer.

A series of ferrocene-pyrazole hybrid compounds were tested against pancreatic cancer (BxPC-3). Compound 11 showed superior anti-cancer effects and low toxicity to normal HK-2 cells, with low hemolytic activity. Proteomics and metabolomics revealed 35 proteins and 58 metabolites with significantly…

Ferrocene-Pyrazole hybrid compound induces ferroptosis and metabolic disruption in pancreatic cancer.

Key Findings

Compound 11 showed highest anti-pancreatic cancer activity with low normal cell toxicity
Low hemolytic activity confirms biocompatibility
Proteomics: 35 proteins with significantly different abundances in treated cells
Metabolomics: 58 metabolites altered (negative mode)
Mechanism involves ferroptosis and metabolic pathway disruption

Implications

Ferrocene-pyrazole hybrids represent a promising class for pancreatic cancer drug development, combining multiple anti-cancer mechanisms.

Caveats

In vitro cell line study; abstract-only. In vivo validation needed. Mechanism characterization from single cell line may not generalize.

Source: Drug development research — 2026-04-01

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

Ferrocene-Pyrazole hybrid compound induces ferroptosis and metabolic disruption in pancreatic cancer.

Key Findings

Implications

Caveats

Read more

Landmark DCIS trial, CRC microbiome & AML combos

Colorectal Cancer Microbiome Discovery Platform

GBM Tumor Microenvironment Drug Target Atlas

BET Inhibitor Target Selectivity Database